Henrijette Richter Ph.D Overview

  • Primary Position
  • Managing Partner

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 8

  • Med. Deal Size

  • Med. Valuation

Henrijette Richter Ph.D General Information

Biography

Dr. Henrijette Richter serves as Managing Partner at Sofinnova Partners. She serves as Vice-Chairman of the Supervisory Board at iOmx Therapeutics. She serves as Board Member at Mozart Therapeutics and Nitrase Therapeutics. Previously, she served as a Partner in the company. She serves as Board Member at Comet Therapeutics,Freya Biosciences, Orphazyme ApS, CytoGuide ApS, Karolinska Development, Delinia, and MycoTeQ A/S (as chairman). She is the Director of Scientific Analysis with Sunstone Capital and an Investment Analyst in Vaekstfondens Life Science Ventures group. A Postdoctoral fellow at Massachusetts Institute of Technology (MIT), Center for Cancer Research. Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen. She is a Board Member of Avilex Pharma. She also serves as Board Member at NodThera. She serves as Board Member at Muna Therapeutics.

Contact Information

Primary Position
Managing Partner, Sofinnova Partners
Education
University of Copenhagen, Ph.D. (Doctor of Philosophy)
University of Copenhagen, MS (Master of Science)
Gender
Female
Email
hr
Phone
+33 01
Address
  • 7-11 Boulevard Haussmann
  • 75009 Paris
  • France
+33 01

Henrijette Richter Ph.D Positions (2)

Firm name Firm type Title Location Industry Since
iOmx Therapeutics Company Vice-Chairman of Supervisory Board Munich, Germany Drug Discovery
Sofinnova Partners Investor Managing Partner Paris, France Venture Capital

Henrijette Richter Ph.D Board Seats (9)

Company Industry Ownership Status Financing Status Location Since
Asceneuron Drug Discovery Privately Held (backing) Venture Capital-Backed Lausanne, Switzerland
Comet Therapeutics Drug Discovery Acquired/Merged Formerly VC-backed Cambridge, MA
Freya Biosciences Biotechnology Privately Held (backing) Venture Capital-Backed Copenhagen, Denmark
iOmx Therapeutics Drug Discovery Privately Held (backing) Venture Capital-Backed Munich, Germany
Mozart Therapeutics Drug Discovery Privately Held (backing) Venture Capital-Backed Seattle, WA

Henrijette Richter Ph.D Lead Partner on Deals (22)

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Asceneuron 16-Jul-2024 Later Stage VC (Series C) Completed Drug Discovery Lausanne, Switzerland
Freya Biosciences 12-Dec-2023 Completed Biotechnology Copenhagen, Denmark
Mozart Therapeutics 07-Jun-2023 Completed Drug Discovery Seattle, WA
Redona Therapeutics 16-Jun-2022 Completed Drug Discovery Watertown, MA
Nitrase Therapeutics 02-Nov-2021 Completed Drug Discovery Brisbane, CA
iOmx Therapeutics 05-Oct-2021 Completed Drug Discovery Munich, Germany
Muna Therapeutics 09-Jul-2021 Completed Drug Discovery Copenhagen, Denmark
NodThera 22-May-2020 Completed Drug Discovery Boston, MA
Comet Therapeutics 13-Jun-2019 Early Stage VC (Series A1) Completed Drug Discovery Cambridge, MA
Comet Therapeutics 05-Nov-2018 Seed Round Completed Drug Discovery Cambridge, MA

Henrijette Richter Ph.D Network (304)

Board Members (139)

Name Company Representing Location From
Nick Haft Freya Biosciences OMX Ventures Copenhagen, Denmark
Rita Balice-Gordon Ph.D Muna Therapeutics Muna Therapeutics Copenhagen, Denmark
Karolinska Development Self Solna, Sweden
Nitrase Therapeutics Self Brisbane, CA
Strategic Partners. EQT Life Sciences Herlev, Denmark

Portfolio Executives (118)

Name Company Role Deal date Location
J. Michael Ryan MD Asceneuron Chief Medical Officer 16-Jul-2024 Lausanne, Switzerland
Dirk Beher Ph.D Asceneuron Co-Founder, Chief Executive Officer & Board Member 16-Jul-2024 Lausanne, Switzerland
Asceneuron Co-Founder, Chief Operating Officer & Vice President, Research & Development 16-Jul-2024 Lausanne, Switzerland
Asceneuron Senior Director & Head of Preclinical Development 16-Jul-2024 Lausanne, Switzerland
Asceneuron Consultant - Head of Non-Clinical Development and Medicinal Chemistry 16-Jul-2024 Lausanne, Switzerland

Fund Team Members (47)

Name Investor Fund Fund Location
Maina Bhaman Sofinnova Partners Sofinnova Capital VIII Paris, France
Maina Bhaman Sofinnova Partners Sofinnova Capital IX Paris, France
Sofinnova Partners Paris, France
Sofinnova Partners Paris, France
Sofinnova Partners Paris, France

Henrijette Richter Ph.D Affiliated Funds (7)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
Novo Ventures 1 Novo Holdings Venture - General Closed 2013
Novo Seeds Novo Holdings Venture Capital - Early Stage Evergreen
Sofinnova MD Start III Fund Sofinnova Partners Venture Capital - Early Stage Closed 2020
Sofinnova Capital IX Sofinnova Partners Venture Capital - Early Stage Closed 2020
Sofinnova Capital VII Sofinnova Partners Venture Capital - Early Stage Closed 2012

Henrijette Richter Ph.D FAQs

  • Who is Henrijette Richter Ph.D?

    Dr. Henrijette Richter serves as Managing Partner at Sofinnova Partners.

  • How much does Henrijette Richter Ph.D typically invest?

    Henrijette Richter Ph.D's median deal size is .

  • What is Henrijette Richter Ph.D’s main position?

    Henrijette Richter Ph.D’s primary position is Managing Partner.

  • What are the contact details for Henrijette Richter Ph.D?

    Henrijette Richter Ph.D’s email address is hr and his phone number is +33 01 .

  • How many active board seats does Henrijette Richter Ph.D hold?

    Henrijette Richter Ph.D holds 9 board seats including Asceneuron, Comet Therapeutics, Freya Biosciences, iOmx Therapeutics, and Mozart Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »